| [Download PDF]
|Year : 2013 | Volume
| Issue : 5 | Page : 524--525
Heart failure induced by itraconazole
Hizir Okuyan1, Cihan Altin2,
1 Department of Cardiology, Sakarya Education and Research Hospital, Adapazari, Sakarya, Turkey
2 Department of Cardiology, Yenimahalle State Hospital, 06370, Ankara, Turkey
Department of Cardiology, Sakarya Education and Research Hospital, Adapazari, Sakarya
Itraconazole is a broad-spectrum antifungal agent. It rarely leads to adverse the cardiovascular effects, especially heart failure. We present here a case of a 60-year-old female patient with itraconazole induced heart failure.
|How to cite this article:|
Okuyan H, Altin C. Heart failure induced by itraconazole.Indian J Pharmacol 2013;45:524-525
|How to cite this URL:|
Okuyan H, Altin C. Heart failure induced by itraconazole. Indian J Pharmacol [serial online] 2013 [cited 2020 Dec 4 ];45:524-525
Available from: https://www.ijp-online.com/text.asp?2013/45/5/524/117751
Itraconazole is a broad-spectrum antifungal agent, used to treat onychomycosis, aspergillosis, blastomycosis and histoplasmosis. It rarely leads to adverse cardiovascular effects. We present here a case of a 60-year-old female patient with itraconazole induced heart failure.
A 60-year-old female patient presented with the complaints of shortness of breath and swelling of the legs for 5 days. She was referred to cardiology clinic and was prescribed 2 × 200 mg/day of oral itraconazole; therapy was initiated 5 days ago by a dermatologist with the diagnosis of onychomycosis. On physical examination, blood pressure was: 130/80 mmHg, cardiac examination was normal, respiratory sounds decreased in basilar of both lungs. There was bilateral pretibial edema. Her electrocardiography and echocardiography were normal. Density in right lower zone and blunting of the right sinus in chest X-ray was observed. Patient was referred to pneumonology clinic. There was no infection or primary pulmonary disease. Patient had no cardiovascular disease or any other cardiac pathology before. The complaints appeared after initiation of itraconazole. According to Framingham study the patients had three minor criteria and major criteria as cause of complaints and findings that's why patients were accepted heart failure. As there was no other cause itraconazole  was considered to be the culprit drug. Oral itraconazole was discontinued and patient was treated with 1 × 40 mg/day furosemide. Patient recovered within a week. Control echocardiography was normal. Exercise stress test was performed to eliminate coronary artery disease, which is a reason for heart failure and the test was normal. Thus, the patient's clinical signs and symptoms were thought to be due to itraconazole and not to any ischemic event with a probable causality relationship as analyzed by World Health Organization - Uppsala Monitoring Center Criteria.
Itraconazole, an azole antifungal agent, is used systemically and it causes dose dependent side effects such as nausea and vomiting. Other frequent side-effects, particularly at high doses (>400 mg/day) are hypokalemia, aspartate aminotransferase elevation, alanine aminotransferase elevation, gastrointestinal disturbances, diarrhea and skin rash. , It very rarely causes congestive heart failure.  The mechanism of heart failure by itraconazole is unknown; however reasons which can lead to heart failure such as hypertension, cardiomyopathy and other possible factors were not present in our patient. And the presence of coronary artery disease in patient was eliminated by a negative stress electrocardiogram test. When itraconazole was administered, the signs and symptoms of heart failure began. And when discontinued it, the signs and symptoms disappeared. That's why, it was thought these findings showed that itraconazole caused signs and symptoms of heart failure. Since 1992, the year that United States Food and Drugs Administration (FDA) approved itraconazole, 58 possible heart failure cases due to itraconazole cases were reported.  For this reason, FDA advise to physicians that the patients with impaired left ventricular function must not be treated by itraconazole, but heart failure can also occur in patients with normal left ventricular function as in our patient. The mechanism of congestive heart failure due to itraconazole is undetermined. Qu et al. showed that itraconazole decreased cardiac contractility, which indicated a direct negative inotropic effect upon the heart.  It is uncertain whether the heart damage is reversible. They also showed that itraconazole decreased heart rate and coronary flow and prolongation of PR and QRS intervals.
This case shows that itraconazole causes cardiovascular adverse-effects such as heart failure and clinicians must take care on this aspect during their treatment with itraconazole. In addition to this itraconazole should not be prescribed to patients with left ventricular systolic dysfunction and heart failure.
|1||Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993;22:6A-13.|
|2||Tucker RM, Haq Y, Denning DW, Stevens DA. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 1990;26:561-6.|
|3||Sharkey PK, Rinaldi MG, Dunn JF, Hardin TC, Fetchick RJ, Graybill JR. High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 1991;35:707-13.|
|4||Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 2001;357:1766-7.|
|5||Qu Y, Fang M, Gao B, Amouzadeh HR, Li N, Narayanan P, et al. Itraconazole decreases left ventricular contractility in isolated rabbit heart: Mechanism of action. Toxicol Appl Pharmacol 2013;268:113-22.|